Prostate cancer affects one in six men in their lifetime, making it one of the most prevalent cancers worldwide. The frontline treatment for prostate cancer is androgen deprivation therapy (ADT), a hormone-based approach aimed at halting tumor progression by cutting off androgen signaling. Yet, despite initial efficacy, ADT frequently loses effectiveness as tumors adapt, giving rise to a more aggressive and treatment-resistant tumor subtype known as neuroendocrine prostate cancer. This transformation, driven by cellular plasticity and lineage reprogramming, has posed a significant challenge to researchers and oncologists seeking durable treatment outcomes.

The phenomenon of lineage plasticity, whereby prostate adenocarcinoma cells undergo transdifferentiation into neuroendocrine-like cells under the selective pressure of ADT, lies at the heart of NEPC progression. Until now, the underlying molecular players orchestrating this transformation were largely unknown. By elucidating the genetic landscape of this progression, the Columbia team aimed to identify novel key drivers enabling tumor adaptability and resistance.

Using a sophisticated forward genetic screen approach in mice, the investigators screened for recurrent mutations across independent prostate tumors that promote the NEPC phenotype. This high-throughput genomic survey revealed 75 candidate genes potentially implicated in driving neuroendocrine features. Among these, Sirtuin 1 emerged as the most compelling and consistent positive regulator. Sirt1 encodes an NAD+-dependent deacetylase enzyme involved in a broad array of cellular functions, including epigenetic regulation, metabolism, DNA repair, and stress responses.

Sirt1’s role in cancer has been contentious, displaying context-dependent activities that can promote or suppress tumor growth depending on the cancer type and cellular environment. However, this new study provides convincing evidence positioning Sirt1 as a potent promoter of NEPC specifically. To validate this, the researchers employed human prostate cancer cell lines characterized by varying levels of SIRT1 expression. Inducing NEPC differentiation in these cells led to increased activation of SIRT1 target genes coupled with suppression of genes usually inhibited by SIRT1, reinforcing the enzyme’s central role in neuroendocrine lineage determination.

Further experiments showed that pharmacologically activating SIRT1 in prostate cancer cells that naturally express it at low levels provoked a robust upregulation of neuroendocrine markers, effectively mirroring the aggressive tumor phenotype. Conversely, silencing Sirt1 expression profoundly curtailed tumor growth in NEPC mouse models. This finding underscores the enzyme’s potential as a therapeutic vulnerability, as its inhibition disrupts the plasticity and dedifferentiation processes essential for tumor aggressiveness.

Perhaps most promisingly, the team evaluated the effects of Selisistat, an FDA-approved SIRT1 inhibitor originally developed for treating Huntington’s disease, on NEPC tumors in vivo. Treatment with Selisistat not only suppressed tumor progression but also notably reversed the neuroendocrine phenotype, indicating that pharmacological disruption of SIRT1 activity could restore tumor sensitivity and undermine lethal cancer progression. This repurposing of Selisistat represents a practical and accelerated pathway toward clinical application.

According to Dr. Cory Abate-Shen, professor at Columbia University Vagelos College of Physicians and Surgeons and co-leader of this research, “Our findings demonstrate that SIRT1 plays a pivotal role in promoting neuroendocrine prostate cancer. This extends beyond general tumor growth regulation to encompass lineage plasticity and cellular identity reprogramming.” This breakthrough highlights SIRT1 as an attractive and clinically actionable target deserving of expedited investigation in future clinical studies.

Complementing this therapeutic insight, the study also elucidates important mechanistic pathways regulated by SIRT1 in NEPC cells. The enzyme’s enzymatic activity influences gene expression patterns that modulate chromatin accessibility and metabolic reprogramming—two fundamental processes implicated in enabling tumor cells to escape differentiation constraints and develop therapy-resistant phenotypes. This dual-level regulation may explain the difficulty encountered in controlling NEPC progression using conventional therapies.

Moreover, by integrating genetic, molecular, and pharmacological data, the research establishes a comprehensive model in which SIRT1 activation masterfully orchestrates the complex network of transcriptional programs necessary for neuroendocrine differentiation. This gene regulatory influence is tightly linked to metabolic adaptations that support tumor survival under androgen-deprived conditions.

The implications of this research are vast, as it paves the way for the development of novel combination therapies that inhibit both androgen receptor signaling and SIRT1 function. Such strategies could effectively thwart the emergence of neuroendocrine prostate cancer at its root, improving patient outcomes and survival rates. Given the current lack of effective treatments for NEPC, these findings may mark a turning point in precision oncology for prostate cancer patients worldwide.

Columbia’s innovative approach, combining forward genetic screening with translational pharmacology, exemplifies the power of integrating genetic discovery with drug repurposing to accelerate clinical impact. While further preclinical validation and clinical trials are warranted, this study positions SIRT1 inhibition as a beacon of hope for tackling the current therapeutic impasse in lethal prostate cancer variants.

As research unfolds, the scientific and clinical communities will closely monitor the progression of SIRT1-targeted therapies through development pipelines. Should these findings be replicated in human clinical contexts, the prospect of significantly extending patient survival and quality of life becomes tangible. This work not only expands our understanding of the molecular underpinnings of cancer plasticity but also sets a blueprint for addressing other malignancies governed by similar mechanisms.

In summary, this landmark study by Nunes de Almeida and colleagues, published on May 28, 2026, in the Journal of Experimental Medicine, identifies Sirtuin 1 as a fundamental genetic driver of neuroendocrine prostate cancer and highlights the therapeutic promise of SIRT1 inhibitors like Selisistat in reversing this aggressive disease phenotype. By revealing the molecular intricacies of lineage plasticity and drug resistance, it invigorates the quest for effective treatments against one of the deadliest forms of prostate cancer.

Subject of Research: Animals
Article Title: A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer
News Publication Date: 28-May-2026
Web References: http://dx.doi.org/10.1084/jem.20241484
References: Nunes de Almeida et al. 2026. Journal of Experimental Medicine
Image Credits: © 2026 Nunes de Almeida et al. Originally published in Journal of Experimental Medicine
Keywords: Prostate cancer, Neuroendocrine prostate cancer, Sirtuin 1, NEPC, Lineage plasticity, Androgen deprivation therapy resistance, SIRT1 inhibitor, Selisistat, Tumor biology, Gene regulation

The transition from hormone-sensitive to castration-resistant disease is characterized by a complex reprogramming of the cancer cells, which can involve changes in their cellular architecture and signaling pathways. As a result, many patients undergoing ADT eventually experience a relapse in their condition. This resilience of the cancer cells brings to light the necessity of investigating additional therapeutic strategies to combat CRPC effectively. In recent years, the development of next-generation AR antagonists and agents that inhibit androgen biosynthesis has marked significant progress in this field, though the emergence of heterogeneous resistance mechanisms has complicated treatment outcomes.

Research has illuminated that even with advanced therapeutic agents, patients can still develop aggressive forms of prostate cancer, including those characterized by double-null phenotypes. This unique form of prostate cancer features both AR-null and neuroendocrine-null characteristics. Such phenotypes present substantial challenges in treatment, rendering conventional therapies suboptimal. Notably, these double-null prostate cancers have been observed in patients who have undergone treatment with agents such as abiraterone and enzalutamide, underscoring the need for a more comprehensive understanding of the underlying mechanisms that facilitate this resistance.

One of the pivotal insights into the mechanism of treatment failure lies in the activation of certain signaling pathways, specifically hepatocyte growth factor (HGF) and canonical WNT signaling. The activation of these pathways has been associated with the reactivation of AR-promoted tumor growth, occurring even when androgen levels are suppressed. This suggests that, despite ADT’s intent to starve cancer cells of their essential growth factors, compensatory biological networks can be upregulated, allowing the cancer to survive and thrive in a hormone-deprived environment.

Furthermore, the interplay between HGF and WNT signaling within the context of prostate cancer resilience indicates a complex regulatory landscape that fosters tumor lineage plasticity. This plasticity enables cancer cells to adapt quickly to therapeutic pressures, evolving into distinct and aggressive phenotypes that exhibit a varied resistance profile. As a result, understanding these molecular mechanisms not only provides essential insights into treatment resistance but also opens new avenues for innovative therapeutic strategies.

As researchers delve deeper into the molecular adaptations underpinning prostate cancer progression post-ADT, they have identified nuclear export mechanisms and ribosomal biogenesis as critical targets for intervention. These processes are intricately linked to the cancer cell’s ability to regulate protein synthesis and export key regulatory components, which are essential for their survival and proliferation. By co-targeting these pathways alongside conventional ADT, clinicians may be able to disrupt the cancer cell’s ability to adapt and overcome therapeutic constraints.

In this respect, the challenge lies not only in the discovery of new drugs but also in devising combination therapies that synergistically inhibit multiple pathways involved in prostate cancer biology. The idea is to harness the knowledge of signaling networks modulated by treatment to anticipate and mitigate potential resistance mechanisms before they emerge. Such an integrated therapeutic framework could significantly enhance patient outcomes and tackle the formidable burden of castration-resistant prostate cancer.

Therefore, as the landscape of prostate cancer treatment evolves, the importance of a multi-faceted approach becomes increasingly clear. By integrating findings on HGF and WNT signaling activation with the latest advancements in therapeutic technologies, researchers and clinicians are better positioned to develop effective management strategies for advanced prostate cancer. Future clinical trials will be critical in validating these approaches and in identifying biomarkers that can predict treatment response more reliably.

Crucially, ongoing research efforts into the cellular and molecular determinants of resistance are likely to illuminate further therapeutic targets. Innovations in precision medicine, which tailors treatment based on the unique genetic and molecular profile of a patient’s tumor, promise to revolutionize the management of prostate cancer. Ultimately, the goal remains not only to extend survival but also to improve the quality of life for patients battling this persistent malignancy.

These recent insights into the resistance mechanisms of prostate cancer highlight an urgent need for increased awareness and research funding dedicated to exploring these pathways. The development of clinically relevant models to study this transition, alongside a commitment to translating laboratory findings into clinical applications, will be vital in the ongoing fight against prostate cancer.

In conclusion, as we stand at the forefront of a new era in understanding prostate cancer biology, it is imperative that collaboration among researchers, oncologists, and patients continues to accelerate discoveries that can lead to effective new therapies. With sustained efforts and a collective commitment to overcoming the complexities of this disease, the future holds potential for significant advancements in the treatment and management of advanced prostate cancer.

Subject of Research: Prostate Cancer and Resistance Mechanisms to Androgen Deprivation Therapy

Article Title: ADT and activation of HGF and WNT axes in double-null prostate cancer

Article References:

Leung, D.H.L., Adzavon, Y.M., Chu, G. et al. ADT and activation of HGF and WNT axes in double-null prostate cancer.
Nat Rev Urol (2026). https://doi.org/10.1038/s41585-026-01129-8

Image Credits: AI Generated

DOI: 10.1038/s41585-026-01129-8

Keywords: Prostate Cancer, Androgen Receptor, Castration-Resistant Prostate Cancer, Androgen Deprivation Therapy, HGF Signaling, WNT Signaling, Therapeutic Resistance, Double-Null Phenotype, Ribosomal Biogenesis, Nuclear Export Mechanisms.

Recent investigations have turned the spotlight on the glutathione S-transferase mu 3 (GSTM3) enzyme, illuminating its intriguing role in the biological dynamics of advanced prostate cancer. GSTM3, classically recognized for its role in detoxification processes and maintaining cellular redox balance, has now been implicated in modulating cancer progression. This emerging evidence positions GSTM3 not only as a biomarker for prostate cancer aggression but also as a promising target for therapeutic intervention.

In a comprehensive study published in BMC Cancer, researchers analyzed GSTM3 expression across a spectrum of prostate cancer models. By leveraging public transcriptomic databases such as GEO and UALCAN, they identified a marked overexpression of GSTM3 in advanced prostate cancer samples. This trend was further validated experimentally using prostate cancer cell lines, including DU-145 and PC-3, as well as three-dimensional tumorsphere cultures that better mimic tumor microenvironments. Remarkably, tumorspheres demonstrated even higher levels of GSTM3, pointing to its potential involvement in tumor initiation and maintenance mechanisms.

To unravel the functional consequences of elevated GSTM3, the researchers employed RNA interference techniques to silence GSTM3 expression in prostate cancer cells. This targeted knockdown approach facilitated a detailed exploration of GSTM3’s influence on key cellular processes. Subsequent assays revealed a complex modulation of intracellular redox status, with silenced cells exhibiting a paradoxical increase in mitochondrial membrane potential (mtMP) alongside a modest reduction in reactive oxygen species (ROS) levels. These findings suggest that GSTM3 contributes to the delicate equilibrium of mitochondrial function and oxidative stress in cancer cells, with potential repercussions for cell survival and proliferation.

Beyond redox regulation, GSTM3 depletion profoundly affected cell cycle progression. Flow cytometric analysis showed a significant arrest at the G0/G1 phase, indicating that GSTM3 may facilitate cell cycle transition and sustained tumor growth. The consequence of this arrest cascaded into enhanced cell death mechanisms, with a notable rise in necrotic cell populations and a modest increase in programmed apoptosis. This dual mode of cell demise hints at a critical dependency of advanced prostate cancer cells on GSTM3 activity for evading lethal stress and maintaining proliferative capacity.

From a therapeutic standpoint, these discoveries open compelling avenues for designing GSTM3-centric treatment strategies. Given its overexpression in aggressive prostate cancer and its regulatory role in key survival pathways, GSTM3 inhibition could synergize with existing therapies to overcome resistance mechanisms. Targeted downregulation of GSTM3 might sensitize tumor cells to chemotherapeutic agents or induce vulnerability to oxidative damage, thereby amplifying treatment efficacy.

The study’s integration of multi-dimensional data—from bioinformatics repositories to in vitro functional assays—provides robust validation of GSTM3 as a critical molecular node in prostate cancer pathobiology. Importantly, the enhanced expression of GSTM3 within tumorspheres underscores its potential involvement in cancer stem cell biology, a domain often linked to tumor relapse and metastasis. Therapeutic intervention targeting GSTM3 could thus impact the aggressive subpopulations driving disease progression.

Future research is primed to elucidate the precise molecular circuits orchestrated by GSTM3, including its downstream targets and interaction with redox-sensitive signaling cascades. Detailed mechanistic insights will be crucial for the rational design of small molecule inhibitors or RNA-based therapeutics aimed at GSTM3. Moreover, translational studies assessing the efficacy and safety of such interventions in preclinical prostate cancer models will pave the way for clinical application.

This innovative focus on GSTM3 aligns with a broader strategy to exploit the cancer cell’s metabolic and oxidative vulnerabilities. By disrupting detoxification enzymes that facilitate tumor cell survival under oxidative stress, researchers can push cancer cells beyond their adaptive thresholds, promoting therapeutic cytotoxicity. GSTM3 emerges as a linchpin in this paradigm, integrating metabolic homeostasis with cell cycle control and death regulation.

Collectively, the affirmation of GSTM3’s oncogenic role reinforces the narrative that advanced prostate cancer necessitates a multi-faceted therapeutic approach. Targeting GSTM3 could shift the current treatment paradigm beyond hormone-based therapies and cytotoxic agents, addressing the molecular underpinnings that sustain tumor resilience and adaptation.

The implications of these findings extend into precision oncology, where monitoring GSTM3 expression levels might serve as a prognostic or predictive biomarker. Stratifying patients based on GSTM3 activity could individualize therapeutic regimens, optimizing clinical outcomes and minimizing adverse effects.

In conclusion, this groundbreaking research spearheaded by Seven, Dalan, and Bayrak spotlights GSTM3 as a viable and compelling candidate for advancing prostate cancer treatment. Their meticulous integration of bioinformatics and experimental validation charts a promising path toward novel, effective therapies. By targeting GSTM3, the oncology community moves closer to overcoming the formidable challenge of advanced prostate cancer, offering hope to patients confronting this relentless disease.

Subject of Research: Glutathione S-transferase mu 3 (GSTM3) in advanced prostate cancer and its potential as a therapeutic target

Article Title: Targeting GSTM3 for therapeutic potential in advanced prostate cancer

Article References:
Seven, D., Dalan, A.B. & Bayrak, Ö.F. Targeting GSTM3 for therapeutic potential in advanced prostate cancer.
BMC Cancer 25, 1493 (2025). https://doi.org/10.1186/s12885-025-14946-8

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14946-8